Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.

L-[18F] fluorodopa was administered in trace amounts intravenously to healthy control subjects and to patients with Parkinson's disease. Striatal uptake of radioactivity was measured using positron emission tomography. The capacity of the striatum to retain tracer was severely impaired in patients compared to controls. This may reflect a reduction of striatal dopamine storage in Parkinson's disease. Patients showing the "on/off" phenomenon had an even greater decrease of striatal storage capacity.

[1]  M. Horne,et al.  A new autoradiographic approach for imaging forebrain dopamine distribution , 1982 .

[2]  M. Kupersmith,et al.  Evaluation of Parkinson's disease. , 1980, Advances in biochemical psychopharmacology.

[3]  G. Firnau,et al.  [18F]Fluoro-dopa, an analogue of dopa, and its use in direct external measurements of storage, degradation, and turnover of intracerebral dopamine , 1978 .

[4]  C. Marsden,et al.  Control of on/off phenomenon by continuous intravenous infusion of levodopa , 1984, Neurology.

[5]  R. Wurtman,et al.  The site of dopamine formation in rat striatum after L-dopa administration. , 1981, The Journal of pharmacology and experimental therapeutics.

[6]  W R Woodward,et al.  The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. , 1984, The New England journal of medicine.

[7]  A. Lees,et al.  On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. , 1984, Brain : a journal of neurology.

[8]  R. S. J. Frackowiak,et al.  Positron emission tomography of the brain: new possibilities for the investigation of human cerebral pathophysiology , 1984, Progress in Neurobiology.

[9]  S. Fahn,et al.  3‐O‐ methyldopa blocks dopa metabolism in rat corpus striatum , 1982, Annals of neurology.

[10]  G. Firnau,et al.  [18F]fluoro-dopa, an analogue of dopa, and its use in direct external measurements of storage, degradation, and turnover of intracerebral dopamine. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Goldstein.  Ergot compounds and brain function : neuroendocrine and neuropsychiatric aspects , 1980 .

[12]  M. Horne,et al.  The cerebral metabolism of L-dihydroxyphenylalanine. An autoradiographic and biochemical study. , 1984, Pharmacology.

[13]  C. Nahmias,et al.  Striatal dopamine metabolism in living monkeys examined by positron emission tomography , 1983, Brain Research.

[14]  C. Nahmias,et al.  Dopamine visualized in the basal ganglia of living man , 1983, Nature.

[15]  G. Firnau,et al.  Intracerebral dopamine metabolism studied by a novel radioisotope technique , 1976, The Journal of pharmacy and pharmacology.

[16]  M E Phelps,et al.  ECAT: a new computerized tomographic imaging system for positron-emitting radiopharmaceuticals. , 1978, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  J. D. de Yébenes,et al.  Effects of 3‐OM‐dopa on monoarnine metabolism in rat brain , 1983, Neurology.

[18]  C. Nahmias,et al.  Central Dopaminergic Pathways in Hemiparkinsonism Examined by Positron Emission Tomography , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[19]  O. Hornykiewicz.  Brain neurotransmitter changes in Parkinson's disease , 1981 .

[20]  R. Chirakal,et al.  Aromatic radiofluorination with [18F]fluorine gas: 6-[18F]fluoro-L-dopa. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  E. Melamed,et al.  Suppression of L‐dopa‐induced circling in rats with nigral lesions by blockade of central dopa‐decarboxylase , 1984, Neurology.

[22]  A. Antonini,et al.  [On-off phenomena in Parkinson's disease. Continuous dopaminergic stimulation]. , 1987, La Clinica terapeutica.

[23]  C. Nahmias,et al.  Blood-brain barrier transport and cerebral utilization of dopa in living monkeys. , 1980, The American journal of physiology.